Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Early cancer detection has significant clinical value, but there remains no single method that
can comprehensively identify multiple types of early-stage cancer. Here, we report the …

Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early
detection are paramount to reducing cancer-related deaths and improving patient outcomes …

Over the last decades, the concept of precision medicine has dramatically renewed the field
of medical oncology; the introduction of patient-tailored therapies has significantly improved …

Over the last decade, liquid biopsy has gained much attention as a powerful tool in
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …

Advances in the enrichment and analysis of rare cells from the bloodstream have allowed for
detection and characterization of circulating tumor cells (CTCs) from patients with cancer …

Detection of circulating tumor DNAs (ctDNAs) in cancer patients is an important component
of cancer precision medicine ctDNAs. Compared to the traditional physical and biochemical …

Liquid biopsy is based on minimally invasive blood tests and has a high potential to
significantly change the therapeutic strategy in cancer patients, providing an extremely …

Background Successful application of programmed death 1 (PD1) checkpoint inhibitors in
the clinic may ultimately benefit from appropriate patient selection based upon predictive …